<DOC>
	<DOCNO>NCT02147301</DOCNO>
	<brief_summary>TACE frequently offer patient baseline hepatic dysfunction purpose diminish hepatic tumor burden patient await transplantation . Without therapeutic measure , disease may progress beyond UNOS T2 criterion require organ allocation . The purpose study determine whether transarterial chemoembolization use doxorubicin-eluting bead ( DEB-TACE ) use safely effectively treat patient liver-only hepatocellular carcinoma ( HCC ) baseline hepatic dysfunction .</brief_summary>
	<brief_title>TACE Using Doxorubicin-eluting Beads Patients With HCC Marginal Hepatic Reserve</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Adult male female patient , age 18 year age old 2 . Diagnosis liveronly HCC base European Association Study Liver ( EASL ) criterion ( radiographic lesion appearance contrastenhanced CT MRI , i.e . enhancement early arterial phase , washout portal venous phase without associate elevation serum AFP level &gt; 200U/ml ) histologic confirmation HCC diagnosis , whichever applicable . 3 . UNOS stage T1 , T2 , T3 disease . 4 . Candidates liver transplantation ( list screen ) accord one follow criterion : 1 . Milan criterion ( one lesion &lt; 5cm 3 few lesion &lt; 3cm ) , 2 . UCSF Downstaging criterion ( one lesion le 8 cm 23 lesion less 5 cm sum maximum dimension less 8 cm , 45 lesion less 3 cm sum maximum dimension less 8 cm ) 3 . UCSF AllComers criterion ( UNOS stage T3 disease beyond UCSF Downstaging Criteria ) . 5 . At least one measurable site disease liver accord RECIST version 1.1 mRECIST criterion . 6 . At least one follow clinical , laboratory , image parameter : 1 . Mild moderate ascites 2 . Serum bilirubin ≥ 3 mg/dl less 6 mg/dl 3 . Aspartate aminotransferase ( AST ) &gt; 5 time upper limit normal ( ULN ) &lt; 10 time ULN 4 . Alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ( ULN ) &lt; 10 time ULN 5. International normalized ratio prothrombin time ( INR ) &gt; 1.5 ≤ 2.5 6 . Portal vein thrombosis ( branch main ) 7 . Functioning transjugular intrahepatic portosystemic shunt ( TIPS ) surgical portosystemic shunt 7 . ECOG performance status 0 , 1 , 2 . 1 . Liverdirected therapy ( chemoembolization , radioembolization , bland embolization , ablative therapy ) within 4 week DEBTACE . 2 . Previous liver transplantation . 3 . Serum bilirubin ≥ 6 mg/dl 4 . AST &gt; 10 time upper normal limit 5 . ALT &gt; 10 time upper normal limit 6 . INR &gt; 2.5 7 . Serum creatinine &gt; 1.5 mg/dl 8 . Macrovascular tumor invasion portal and/or hepatic vein ( ) 9 . Extracapsular tumor extension 10 . Extrahepatic disease 11 . Hepatic encephalopathy refractory medical therapy 12 . Active uncontrolled infection 13 . Imaging evidence common bile duct obstruction 14 . Previous sphincterotomy bilioenteric anastomosis 15 . Significant hepatic arterial portal vein shunt area treat . 16 . Symptomatic congestive heart failure ( CHF ) 17 . Allergy intolerance prior doxorubicinbased TACE 18 . Allergy intolerance iodinate contrast medium despite standard care premedication 19 . Any contraindication treatment LC Bead™ device ( e.g . patient large diameter arteriovenous shunt patient righttoleft shunt ) . 20 . Systemic therapy sorafenib systemic chemotherapeutic agent ( ) less 1 week prior first plan DEBTACE . 21 . Active second malignancy nonmelanoma skin cancer cervical carcinoma situ . ( Patients history malignancy consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse . ) 22 . Uncontrolled intercurrent illness include , limited : Ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled cardiac arrhythmia , uncontrolled peripheral vascular disease , myocardial infarction within precede 12 month , cerebrovascular accident within precede 12 month , pulmonary disease impair functional status require oxygen , impairment gastrointestinal function may affect alter absorption oral medication ( malabsorption history gastrectomy bowel resection ) . 23 . Pregnant lactate woman exclude study potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother DEBTACE , breastfeed must discontinue eligibility . 24 . Psychiatric illness , significant medical illness , social situation , investigator 's opinion , would limit compliance ability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>